Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Olympus
Pharma
GSK-Hengrui, Takeda, Celltrion—Fierce Pharma Asia
GSK signed a 12-asset licensing deal with Hengrui. Generic erosion on Vyvanse pulled back Takeda. Celltrion plans to buy a large U.S. facility.
Angus Liu
Aug 1, 2025 9:00am
RemeGen, Harbour, Datroway—Fierce Pharma Asia
Jun 27, 2025 8:37am
Big Pharma CEOs in China, AstraZeneca, WuXi—Fierce Pharma Asia
Mar 29, 2024 10:10am
Olympus mounts lung cancer education push with advocacy group
Mar 27, 2024 12:13pm
Big Pharma deal spree, China plans and more—Fierce Pharma Asia
Jan 5, 2024 8:44am
Hengrui, Takeda, and toripalimab's FDA nod—Fierce Pharma Asia
Nov 3, 2023 8:30am
